| Bioactivity | Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibitor. Libenzapril has the potential for ischemia-induced heart failure research[1]. |
| CAS | 109214-55-3 |
| Formula | C18H25N3O5 |
| Molar Mass | 363.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. E F Smith 3rd, et al. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat. Pharmacology. 1988;37(4):254-63. |
Libenzapril
CAS: 109214-55-3 F: C18H25N3O5 W: 363.41
Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.